Close Menu

Out of Academia

In a blog post at DeviceRandom, Massimo Sandal says why he left not only his chemistry postdoc at the University of Cambridge, but also why he chose to leave academia altogether. While he wasn't overly optimistic about his most recent research project, Sandal says he chose to leave the lab because he thinks there are problems within the "practice of science itself." While he says he still loves science, he's not so enamored with the high-stakes "competition for funding and positions" he's seen within it.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.